Recent Biotech News: Altimmune’s Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback
Altimmune announced positive 48-week topline results from the IMPACT Phase 2b trial of pemvidutide in MASH on December 19, 2025, showing significant reductions in ALT (-37.4 to -37.8 IU/L vs. -10.3 placebo), cT1 (-124 to -140 ms vs. -21 ms), ELF, and LSM, supporting antifibrotic activity.1
Pemvidutide doses of 1.2 mg and 1.8 mg met key noninvasive fibrosis markers, with FDA alignment for registrational Phase 3 trial in MASH patients with moderate to advanced fibrosis, planned for 2026; AI integration like AIM-MASH approved.1
Earlier AI-based analysis from IMPACT trial at 24 weeks showed significant liver fibrosis reductions and MASH resolution up to 58% with pemvidutide vs. placebo.2
No specific recent news in results on new China obesity biotech; search lacks details on emerging players.
No specific recent news in results on Ipsen Phase 2 failure; search lacks details on this trial outcome.
Sources:
1. https://www.barchart.com/story/news/36709912/altimmune-announces-that-pemvidutide-achieved-key-measures-of-success-at-48-weeks-in-impact-phase-2b-mash-trial
2. https://www.biospace.com/press-releases/altimmune-presents-ai-based-analysis-of-liver-fibrosis-reduction-from-impact-phase-2b-trial-of-pemvidutide-in-mash-in-late-breaking-poster-at-aasld-the-liver-meeting-2025